Approval granted for reimbursement of Extracorporeal Photopheresis (ECP) for Bronchiolitis Obliterans Syndrome (BOS) derived from lung transplantation. First approval of a Health Technology Appraisal for ECP in BOS by a...
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
Following CVC’s acquisition of the Therakos company, some systems and services will continue to be operated by Mallinckrodt Pharmaceuticals under the Transition Services Agreement (TSA), which is the reason for your redirection.
The Therakos company does not review or control the content of non-Therakos company websites. Therakos privacy procedures do not apply to the owners of a non-Therakos Group websites.